SKB BIO (06990) saw its shares climb nearly 3% in late trading. At the time of writing, the stock was up 2.24%, trading at HK$475, with a turnover of HK$235 million. The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is scheduled to take place from May 29 to June 2 in Chicago, USA. According to an announcement on SKB BIO's official social media account, the company will present clinical research results for three assets at the conference: the TROP2 ADC sacituzumab tirumotecan (sac-TMT, marketed as Jiatailai®), the next-generation selective RET inhibitor A400/EP0031 (fumarate form, marketed as Ningtailai®), and the novel ADC SKB500. Full abstracts of the related studies will be published on the official ASCO website on May 21, 2026, local time.